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To evaluate the reproductive performance and the development of
their offspring on rat pregnancy, Wistar pregnant rats were gavaged
with 0 mg/kg wb/day (control group, n = 20) and 166.5 mg/kg/day
of a mixture of vitamin C, hesperidin and piperidol (experimental
group, n= 20) during the organogenic period (from day 5 to 14 of
pregnancy; positive vaginal smear = day 0). The female rats were
killed on day 21 of pregnancy. The number of implantations,
resorptions (dead embryos), and live/dead fetuses were counted
for the analysis of the postimplantation loss rates. There was neither
alteration in maternal reproductive performance, but it was verified
an increase of the number of fetuses presenting dilated urether,
hydronephrosis, and reduced ossification of skull due to the
treatment of female rats with a mixture of vitamin C, hesperidin
and piperidol, these abnormalities were considered transitory and
may not interfere on offspring development. It was not verified other
type of major malformation neither the appearance of fetuses
presenting atrophy of upper limbs that it could be associated to
use of this drug.
INTRODUCTION
To evaluate real effect of a certain toxicant chemical
agent in a pregnant woman, we should verify if the kinetic
process in this organism is modified and consider the ma-
ternal-placental-fetal unit. Although a placental membrane
exists between mother and fetus, this function is limited,
because it depends on the physical characteristics of the
substance transferred. These substances may cross the pla-
centa by passive or facilitated diffusion, active transport,
pinocytosis and breaks between the cells present in the
placental membrane, causing deleterious effects on the
embryo (Sadler, 2004). Elimination of drugs from the
embryo or fetus is considered to be almost entirely
dependent on the mothers. There is a low capacity of
metabolizing of drugs in the fetal liver and an immaturity of
the renal excretion. The role of the fetal kidney as a route of
drug elimination seems to be insignificant (Fouts, 1973).
Several drugs are used during the gestation to
prevent the premature uterine contractions. A mixture of
ascorbic acid (50 mg), hesperidin complex (50 mg) and
piperidolate chloridrate (100 mg) is used as muscular
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relaxant with aim of avoiding abortion and premature birth
(Okumura, Kim, 1965; Watanabe et al., 1966). Although
clinical studies were done with a mixture of vitamin C,
hesperidin and piperidol to prevent premature uterine
contractions based on its anticholinergic effect, it has been
suggested that certain antispasm drugs may produce
malformations via their effect on the acetylcholine and
choline levels in the fetus (Moore, Persaud, 2004).
A great number of experimental studies have indicated
that prenatal administration of hundreds of drugs can result
in fetal death, malformations, growth suppression, and
postnatal structural and functional developmental anomalies.
The route of chemical exposure, selection and care of the
experimental animals, environmental variables (caging, diet,
temperature, and humidity), careful selection of dose levels
and interpretation of results are important factors considered
in toxicity testing (WHO, 2004).
At the Ambulatory of Clinical Genetic, School of
Medicine of Marilia, São Paulo, Brazil (FAMEMA), there
were reports of the three women that ingested mixture of
vitamin C, hesperidin and piperidol during pregnancy, but
exact gestational period is unclear, and their offspring presented
atrophy of upper limbs. Considering doubt about involvement
of the mixture of vitamin C, hesperidin and piperidol in
occurrence of malformations, the present study was conducted
to evaluate the reproductive performance and incidence of fetal
malformations of rats treated with this mixture.
MATERIAL AND METHODS
Animals
Wistar female and male albino rats (200 ± 20 g) were
kept in a controlled room (22 ± 3 oC) with a 12/12 h light/
dark cycle. Animals had free access to food pellets (Purina®
rat chow, Paulinia, São Paulo State, Brazil) and tap water ad
libitum. All experimental procedures involving animals
were approved by the ethical animal committee of the
School of Medicine of Botucatu, São Paulo, Brazil.
Drugs
The control group received 0 mg/kg of the mixture of
vitamin C, hesperidin and piperidol. Two tablets of the
mixture of vitamin C, hesperidin and piperidol (166.5 mg/kg)
diluted into distilled water were administered to experimental
group (n = 20). The administered dose was five times higher
than that used for human (the dose daily ingested by a woman
weighing 60 kg is approximately 33.5 mg/kg). The rat dose
chosen was higher than that in woman treatment because of
the sensibility difference among species (Lemonica, 2004).
Experimental procedure
Virgin female rats were mated overnight with adult
Wistar male rats of the same strain. The morning sperm-
positive vaginal smears were detected and day 0 of gestation
was considered. The mated rats were divided at random into
two groups: G1= control (distilled water), and G2= treated
with mixture of vitamin C, hesperidin and piperidol. Each
group received daily the treatment by gavage during the
organogenic period of days 5-14 of pregnancy. Maternal
weight gain was measured at morning (9:00 A.M.) of the days
0, 7, 14 and 21 of pregnancy. All pregnant animals were killed
on GD21 for evaluation of the number of implantation,
resorption (dead embryo) and live fetuses were counted. The
rate of postimplantation loss was calculated as: (Number of
Implantation - Number of live fetuses)/ (Number of
Implantation) x 100. The fetuses and their placentas were
dissected from the uterus, inspected for gross morphologic
abnormality and weighed. After weighing, the fetuses were
classified as small (SPA), appropriate (APA) and large (LPA)
for pregnancy age compared to fetal body weight mean of the
control group. The placental index was calculated as:
Placental Weight/Fetal Corporal Weight (Calderon et al.,
1992). The non-observed embryonic implantation was
stained with Salewski method (Salewski, 1964). Fetuses
were also evaluated in a microscope with respect to incidence
of external malformation and anomaly. After external
analysis of the fetuses, half the fetuses were fixed in Bouin’s
fluid and serial sections were prepared as described by
Wilson (1965) for visceral examination. The remaining
fetuses were prepared for examination of the skeletons by the
staining procedure of Staples and Schnell (1964). The
malformation term was considered when an incompatible
structural abnormality with the survival was founded and
anomaly term when an alteration of the normal process of the
development was observed, but there was no alteration on
the general or specific function nor on the individual
development (Wilson, 1965; Traballi et al., 2000).
Statistical analysis
Results are presented as mean ± standard deviation
(SD). Data were analyzed by one-way ANOVA, Chi-
square and Goodman tests (Zar, 1999). Differences were
considered statistically significant when P<0.05.
RESULTS
Reproductive performance
At day 21 of pregnancy, the reproductive perfor-
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mance of the dams treated with mixture of vitamin C,
hesperidin and piperidol during organogenic period was
similar to that of the control group (Table I). There was no
significant difference in the mean number of implantation
sites. There was a mean of 11.4 ± 3.5 live fetuses in the
control group, and 10.9 ± 2.8 in the treated group. The rate
of loss of the embryos after implantation was not different
compared to the control (Table I).
Fetal and Placental Analysis
Exposure to the mixture of vitamin C, hesperidin
and piperidol did not significantly alter fetal weight
throughout the pregnancy (Figure 1), neither the fetal
classification for pregnancy age (Figure 2). The placental
weight and index showed no statistical difference
compared to the control group (Figure 1).
Incidence of fetal malformation and anomaly
The analysis of the incidence of external mal-
formation and anomaly was accomplished in 448 fetuses.
Two of the 20 litters (12 fetuses) of the control group and
two of the 20 litters (13 fetuses) of the mixture of vitamin
C, hesperidin and piperidol group were discarded because
the fetuses were dissolved during skeletal preparation that
did not permit fetal analysis (Table II). Female rats treated
with the mixture presented higher occurrence of fetal
visceral malformation, and also skeletal and visceral
anomalies compared to the control group. The rate of
reduced ossification of skull, a type of skeletal anomaly
was increased in fetuses of rats treated with mixture
compared to the control group. The visceral malformation
observed was hydronephrosis, the skeletal anomaly
presented was reduced ossification, and the visceral
anomaly verified was enlarged urether (hydrourether)
(Table II).
DISCUSSION
Although safety evaluation of exposure to chemicals
is generally based on studies of single compounds, humans
are exposed to combination of chemicals. The difficulties of
FIGURE 2 - Incidence (percentage) of fetuses classified as
small (SPA), appropriate (APA) and large (LPA) for the
pregnancy age of Wistar rats treated with a mixture of vitamin
C, hesperidin and piperidol during the organogenic period.
(No difference (p > 0.05) compared to the control group).
TABLE I – Reproductive performance of  Wistar rats
treated with a mixture of vitamin C, hesperidin and
piperidol during the organogenic period.
Groups Control Treated
No females
   mated 20 20
   pregnant 20 20
Number of total resorptions 0 0
Number of corpora-lutea 13.1 ± 1.5 13.8 ± 2.4
Number of implantation 12.2 ± 2.5 11.9 ± 2.2
Number of live fetuses 11.4 ± 3.5 10.9 ± 2.8
Mean postimplantation loss (%) 7.0 7.9
Maternal weight gain (g) 80.2 ± 24.3  77.8 ± 19.5
No difference (p > 0.05) compared to the control group
FIGURE 1 - Fetal weight, placental index and weight of
Wistar rats treated with a mixture of vitamin C, hesperidin
and piperidol during the organogenic period. (No
difference (p > 0.05) compared to the control group).
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toxicity studies with mixtures are broadly acknowledged
and a source of continued concern. The extreme complexity
of mixture toxicity has suggested new research methodo-
logies to study interactive effects (taking into account
limited resources), including statistical designs and
mathematical modeling of toxicokinetics and toxico-
dynamics. Complex mixtures likely produce more
unexpected results than individual chemical substances.
Mixtures are composed of various substances, exposure to
which can be expected to be associated with different
toxicities. The constituents of a mixture sometimes combi-
ne chemically to produce new compounds with different
toxicities. Additionally, the presence of some mixtures
might mask, dilute or increase toxicity of other materials.
Such phenomena, referred to as interactions, can amplify or
reduce anticipated results. Another consideration is that
different doses of separate materials might increase the
bioavailability of materials that are otherwise non-toxic at
the doses present in the mixture. The potential adverse
impacts of chemicals are dependent on a number of factors
including levels and duration of exposure, the mechanism
of action and interactions among chemicals in a mixture. It
should be noted that hazard and risk assessment of
chemicals performed by regulatory agencies have primarily
focused on the toxicities of individual compounds and to a
remarkably diminished extent to mixtures (WHO, 2004).
Literature presents no data about reproductive
performance and fetal repercussions after mixture of
vitamin C, hesperidin and piperidol treatment. The present
results showed that this mixture administration cause no
maternal toxicity, because there was no difference in the
mean corporal weight gain of the female rats of the different
groups. There is no published evidence about fetal
abnormalities caused by of vitamin C and hesperidin
administered by oral gavage to rats during organogenic
period. In this study, a mixture of vitamin C, hesperidin and
piperidol treatment caused no embryonic death and it did
not influence placental weight. The weight classification of
the fetuses for pregnancy age was similar between control
and experimental groups, showing that the drug mixture
caused no influence on fetal weight. Nevertheless, this
study revealed that a mixture of vitamin C, hesperidin and
piperidol interfered in the development of the urinary
system, because it was capable to induce enlarged urether
(41.9% of the fetuses) and hydronephrosis (11.4% of
fetuses). The grave dilatation of the urether is recognized
easily because the extensive urether are molded in “S” or
twisted, completely transparent and, then, easily
identifiable, as observed in this study. Besides, the enlarged
urether may or not to be associated to the congenital
hydronephrosis and any pelvic alteration, which may be
considered transitory in rodents (Taylor, 1986). Damasceno
et al. (2002) verified  that 10 to 20% of the fetuses from
female control rats also presented this type of visceral
anomaly. The reduced ossification of skull in fetuses of rats
treated with mixture might be considered transitory.
Nishimura and Tanimura (1976) reported that a girl with
severe skull defect and growth retardation due to her
mother’s ingestion of drug pregnancy has later shown great
improvement in physical growth and her mental and soci-
al development are normal at age of nine.
In spite of the increase of the number of fetuses
presenting dilated urether, hydronephrosis, and reduced
ossification of skull due to the treatment of female rats with
a mixture of vitamin C, hesperidin and piperidol, these
abnormalities were considered transitory and may not inter-
TABLE II – Incidence of fetal malformation and anomaly
of Wistar rats treated with a mixture of vitamin C,
hesperidin and piperidol during organogenic period
Groups Control Treated
External Malformation
Affected Litters 0/20 2/20
Affected Fetuses 0/227 2/221
Macroglossia 0/227 2/221
Skeletal Anomaly
Affected Litters 14/18 16/18
Affected Fetuses 28/104 51/103*
14th rib 10/104 14/103
Butterfly vertebrae 1/104 4/103
Cleaved vertebrae 7/104 3/103
Rudimentar sternebrae 4/104 2/103
Inshaped sternebrae 9/104 15/103
Supranumerary sternebrae 0/104 2/103
Reduced ossification of skull 9/104 23/103*
Skeletal Malformation
Affected Litters 5/18 3/18
Affected Fetuses 6/104 4/103
Cleft palate 6/104 4/103
Visceral Anomaly
Affected Litters 4/20 19/20*
Affected Fetuses 29/111 45/105*
Enlarged urether 29/111 44/105*
Hyperplasic bladder 0/111 1/105
Visceral Malformation
Affected Litters 2/20 10/20*
Affected Fetuses 3/111 12/105*
Hydronephrosis 3/111 12/105*
* Difference (p< 0.05) compared to the control group
(Goodman test)
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fere on offspring development. It was verified neither other
type of major malformations nor the appearance of fetuses
presenting atrophy of upper limbs that it could be associated
to use of this drug. Thus, considering doubt about
involvement of this mixture in occurrence of malformations
on offspring from women that ingested this drug during the
gestational period, this study showed that rodents exposed
to the drugs present no alteration on the development of the
limbs during the organogenic period in the experimental
conditions carried out.
RESUMO
Exposição à mistura de vitamina C, hesperidina e
piperidol durante a gravidez: repercussões
materno-fetais
Para avaliar a performance reprodutiva de ratas e o de-
senvolvimento de seus filhotes, ratas Wistar prenhes fo-
ram tratadas por gavage com 0 mg/kg peso corpóreo/dia
(grupo controle, n = 20) e 166,5 mg/kg/dia de mistura de
vitamina C, hesperidina e piperidol (grupo experimental,
n= 20) durante o período organogênico (do 5o ao 14o dia
de prenhez, considerando esfregaço vaginal positivo = dia
1). As ratas foram mortas no 21o dia de prenhez. O número
de implantações, reabsorções (morte embrionária) e os
fetos vivos e mortos foram contados para avaliação da
taxa de perda pós-implantação. Não houve alteração na
performance reprodutiva materna, mas foi verificado au-
mento no número de fetos com uretér dilatado,
hidronefrose e ossificação reduzida do crânio devido ao
tratamento das ratas com a mistura de vitamina C,
hesperidina e piperidol. Essas anormalidades foram con-
sideradas transitórias e não interfeririam no desenvolvi-
mento dos filhotes. Não foram observados outros tipos de
malformações amiores e os fetos também apresentaram
atrofia dos membros superiores que pudesse estar relaci-
onado ao uso desta mistura..
UNITERMOS: Mistura de vitamina C. hesperidina e
piperidol. Gravidez. Repercussões maternas. Ratos.
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